GenScript is a life sciences technology company that provides integrated research, discovery, and development platforms spanning genes, proteins, antibodies, mRNA, and gene-editing solutions to help accelerate biotechnology innovation.
GenScript has evolved from a research tools company into a much broader life sciences platform. How do you define the company’s essence and mission today?
Our essence and mission have not changed since we started. We were born to accelerate biotechnology innovation. It began with a simple but powerful idea from our founder: to make DNA synthesis easier, quicker, and more accessible for researchers globally. At the time, getting clone work done could take months, and he experienced that frustration firsthand. The original goal was to make gene synthesis and molecular biology faster, higher-throughput, and commercially accessible.
That idea has since expanded into a broader infrastructure spanning genes, proteins, antibodies, mRNA, and gene-editing materials and reagents. But the mission remains the same. Speed is becoming more and more critical for pharmaceutical companies, biotech innovators, and academic labs. Everyone wants to be first in class and best in class. We believe the infrastructure we are building at GenScript is essential to that ecosystem, and we are proud of what we have achieved over the past two decades.
What differentiates you from competitors?
That is a question we ask ourselves every day: how do we stay competitive and keep our edge? I would say the answer is the integration of our proprietary platforms. That mindset and execution are what differentiate us.
Our new tagline, “Scripting Possibilities,” reflects the idea that many things once seen as impossible are now possible, and it is our job to make them happen.
More and more, our conversations with customers are about whether we can get something done at a certain speed, with reliability, and at scale.
That is why we have been integrating our platforms into more complete solutions. For example, from gene synthesis to antibody expression and purification, we can now do it within five business days through what we call the TurboCHO platform. That is unheard of. In the past, getting results validated or screened could take four months or longer. In today’s AI-assisted drug discovery environment, scientists can design huge numbers of candidates, but design is only the first step. Those candidates still have to be built and tested, and that design-build-test-learn cycle has to move much faster.
Can you give a concrete example of the kind of challenge GenScript helps clients solve?
This is our daily work. At the discovery stage, scientists may know the target and want to develop an antibody therapeutic with a certain potency, developability profile, and IP position. They design thousands of sequences, and now those designs are not just monoclonals but also bispecifics, trispecifics, and other increasingly complex formats. The designs are becoming more creative and sophisticated, and people need to know quickly whether they actually work.
To do that, the sequences need to be synthesized, expressed, purified, and then tested. That is becoming more critical because wet-lab data need to feed back into the design algorithms. The sequence gets screened, improved, relearned, and redesigned in cycles. This is especially important at the lead-generation stage, where companies want to shorten time to clinic and capture more developability data as early as possible. The earlier those data are captured, the faster later-stage development can move.
Are you already seeing a meaningful reduction in time to clinic?
Yes, absolutely. This is already happening. It is a requirement pharmaceutical companies are setting for themselves. Many have tried to build these capabilities in-house, but they are increasingly realizing that GenScript can do this better than their internal platforms. Our goal is to shorten the R&D cycle by 50%, and that is what we are driving toward.
That reduction is not only about speed. Reliability is non-negotiable. Data integrity and the quality of what we deliver cannot be compromised. In the past, rational design often meant working on hundreds of sequences because building and testing were too slow and expensive. Now people are working on thousands, sometimes tens of thousands, of designs under much shorter timelines, and it all still has to be affordable. That is why scale matters so much.
Where is AI genuinely improving drug discovery today, and what role does GenScript play in that process?
The major challenge is data. The input is thousands or hundreds of thousands of designed sequences, and the output is potency, physical properties, and other performance characteristics. To make AI algorithms work well, you need a great deal of output data. The field still lacks enough wet-lab data, and just as importantly, it lacks negative data. We know a lot about what works, but knowing what does not work is often even more critical for training the algorithm.
That is why more testing and more design cycles are still needed. Today, AI can predict certain single properties, such as aggregation or binding, with reasonable accuracy, but biology in cells and in the human body is much more complicated. There is still a long way to go. Our role at GenScript is to provide the discovery infrastructure for that ecosystem. We operate at a throughput and scale that are very hard to match, and that makes us critical in generating the experimental data that AI-driven drug discovery still depends on.
How is GenScript thinking about manufacturing capacity and its broader global strategy?
This is not only about U.S. manufacturing. It is also about the U.K. and global operations more broadly. From day one, we have wanted to deliver what we build to customers more quickly, and logistics are a critical part of that. When turnaround times were measured in months, shipping was a smaller part of the equation. But when you can get the work done in five days, shipping time becomes a major bottleneck. The conclusion is clear: we have to be closer to our customers.
That has been embedded in our strategy for years. In the U.S., we have three sites in New Jersey with highly automated operations. We have also expanded in Singapore and the Netherlands. We invest heavily in automation, engineering, and platform improvement, and devote 8% of our revenue every year to R&D. Increasingly, we are also extending our protocols and technologies into customers’ own labs. In the past we saw this as proprietary, but now we see that enabling customers in-house is more scalable, strengthens the relationship, and benefits both sides.
What are your top priorities for the next 12 months?
The first is further platform integration and innovation. Internally, we think in versions, always asking how to raise the standard in scale, turnaround, and complexity. Right now, gene to antibody can be done in five business days, but we are already asking whether we can do it in three. We are constantly looking for ways to remove steps and save time, because every half day and every half hour counts.
The second priority is to build more scale through automation, making our systems more reliable, more robotic, and more profitable across our global sites. The third is product transformation: turning what we do internally into solutions customers can use in-house in a customized way. So the focus for the next year is clear: keep innovating the platforms, keep expanding the infrastructure through automation, and keep extending those capabilities into products customers can integrate into their own labs.
